Compare ASE Technology Holding Co Ltd (ASX) vs Pfizer Inc (PFE) Price & Performance

ASE Technology Holding (ASX) trades at $37.39, up 0.38% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.29, beating estimates of $0.23, and announced a $10.5 billion capital expenditure increase for AI-driven growth (Reuters, July 30, 2026). Revenue rose to $645.39 billion in 2025, with net income of $40.02 billion, while valuation ratios like P/E of 46.26 suggest premium pricing.

Outlook remains positive due to AI semiconductor demand and margin expansion, but risks include high valuation and competitive pressures. Analysts are largely bullish with 80% buy ratings, though the stock faces volatility near resistance at $38.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.